Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout
Authors' conclusion
Several patient-level factors were predictive of SU goal achievement among patients with gout who received treat-to-target urate-lowering therapy (ULT).
Study context
- Population
- Participants with gout and serum urate (SU) ≥6.8 mg/dL randomised to allopurinol or febuxostat, titrated weeks 0 to 24 and maintained weeks 25 to 48764 completing week 48
- Primary endpoint
- SU goal achievement: mean SU from weeks 36, 42 and 48 <6.0 mg/dL (<5 mg/dL if tophi present)
- Follow-up
- Weeks 36, 42 and 48
Methodological detailsmultivariable logistic regression, preselected determinants, additional analyses accounting for treatment adherence
- Multivariable logistic regression
- Preselected determinants
- Additional analyses accounting for treatment adherence
Primary result
As reported in the abstract
week 48
- Achieved SU goal
- 618 (81%)
- Older age, aOR per 10 years
- 1.40
- Higher education, aOR
- 2.02
- Better health-related quality of life (HRQoL), aOR per 0.1 unit
- 1.17
- Non-White race, aORs
- 0.32-0.47
- Higher baseline SU, aOR per 1 mg/dL
- 0.83
- Presence of tophi, aOR
- 0.29
- Diuretic use, aOR
- 0.52
Original publication
Determinants of Achieving Serum Urate Goal with Treat‐to‐Target Urate‐Lowering Therapy in Gout. Arthritis Rheumatol. Published 26 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →